247 related articles for article (PubMed ID: 16951201)
1. Farnesyltransferase inhibitors reverse taxane resistance.
Marcus AI; O'Brate AM; Buey RM; Zhou J; Thomas S; Khuri FR; Andreu JM; Díaz F; Giannakakou P
Cancer Res; 2006 Sep; 66(17):8838-46. PubMed ID: 16951201
[TBL] [Abstract][Full Text] [Related]
2. The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase.
Marcus AI; Zhou J; O'Brate A; Hamel E; Wong J; Nivens M; El-Naggar A; Yao TP; Khuri FR; Giannakakou P
Cancer Res; 2005 May; 65(9):3883-93. PubMed ID: 15867388
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma.
Kim ES; Kies MS; Fossella FV; Glisson BS; Zaknoen S; Statkevich P; Munden RF; Summey C; Pisters KM; Papadimitrakopoulou V; Tighiouart M; Rogatko A; Khuri FR
Cancer; 2005 Aug; 104(3):561-9. PubMed ID: 16028213
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative.
Taraboletti G; Micheletti G; Rieppi M; Poli M; Turatto M; Rossi C; Borsotti P; Roccabianca P; Scanziani E; Nicoletti MI; Bombardelli E; Morazzoni P; Riva A; Giavazzi R
Clin Cancer Res; 2002 Apr; 8(4):1182-8. PubMed ID: 11948131
[TBL] [Abstract][Full Text] [Related]
5. Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies.
Dumontet C; Jordan MA; Lee FF
Mol Cancer Ther; 2009 Jan; 8(1):17-25. PubMed ID: 19139109
[TBL] [Abstract][Full Text] [Related]
6. Antitumour activity of novel taxanes that act at the same time as cytotoxic agents and P-glycoprotein inhibitors.
Ferlini C; Distefano M; Pignatelli F; Lin S; Riva A; Bombardelli E; Mancuso S; Ojima I; Scambia G
Br J Cancer; 2000 Dec; 83(12):1762-8. PubMed ID: 11104578
[TBL] [Abstract][Full Text] [Related]
7. Taxanes with high potency inducing tubulin assembly overcome tumoural cell resistances.
Matesanz R; Trigili C; Rodríguez-Salarichs J; Zanardi I; Pera B; Nogales A; Fang WS; Jímenez-Barbero J; Canales A; Barasoain I; Ojima I; Díaz JF
Bioorg Med Chem; 2014 Sep; 22(18):5078-90. PubMed ID: 25047938
[TBL] [Abstract][Full Text] [Related]
8. Tubulin interacting agents: novel taxanes and epothilones.
Agrawal NR; Ganapathi R; Mekhail T
Curr Oncol Rep; 2003 Mar; 5(2):89-98. PubMed ID: 12583825
[TBL] [Abstract][Full Text] [Related]
9. Taxane- and epothilone-based chemotherapy: from molecule cargo cytoskeletal logistics to management of castration-resistant prostate carcinoma.
Alberti C
Eur Rev Med Pharmacol Sci; 2013 Jun; 17(12):1658-64. PubMed ID: 23832735
[TBL] [Abstract][Full Text] [Related]
10. Taxane refractory prostate cancer.
Mathew P; Dipaola R
J Urol; 2007 Sep; 178(3 Pt 2):S36-41. PubMed ID: 17644120
[TBL] [Abstract][Full Text] [Related]
11. Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer.
Tan MH; De S; Bebek G; Orloff MS; Wesolowski R; Downs-Kelly E; Budd GT; Stark GR; Eng C
Breast Cancer Res Treat; 2012 Feb; 131(3):849-58. PubMed ID: 21479552
[TBL] [Abstract][Full Text] [Related]
12. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells.
Giannakakou P; Gussio R; Nogales E; Downing KH; Zaharevitz D; Bollbuck B; Poy G; Sackett D; Nicolaou KC; Fojo T
Proc Natl Acad Sci U S A; 2000 Mar; 97(6):2904-9. PubMed ID: 10688884
[TBL] [Abstract][Full Text] [Related]
13. Cellular bases of the antitumor activity of the novel taxane IDN 5109 (BAY59-8862) on hormone-refractory prostate cancer.
Cassinelli G; Lanzi C; Supino R; Pratesi G; Zuco V; Laccabue D; Cuccuru G; Bombardelli E; Zunino F
Clin Cancer Res; 2002 Aug; 8(8):2647-54. PubMed ID: 12171897
[TBL] [Abstract][Full Text] [Related]
14. miR-130a activates apoptotic signaling through activation of caspase-8 in taxane-resistant prostate cancer cells.
Fujita Y; Kojima T; Kawakami K; Mizutani K; Kato T; Deguchi T; Ito M
Prostate; 2015 Oct; 75(14):1568-78. PubMed ID: 26074357
[TBL] [Abstract][Full Text] [Related]
15. Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models.
Sampath D; Greenberger LM; Beyer C; Hari M; Liu H; Baxter M; Yang S; Rios C; Discafani C
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3459-69. PubMed ID: 16740771
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in the new generation taxane anticancer agents.
Geney R; Chen J; Ojima I
Med Chem; 2005 Mar; 1(2):125-39. PubMed ID: 16787308
[TBL] [Abstract][Full Text] [Related]
17. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
Sebti SM; Hamilton AD
Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
[TBL] [Abstract][Full Text] [Related]
18. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
Goble S; Bear HD
Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
[TBL] [Abstract][Full Text] [Related]
19. Relationship between the structures of taxane derivatives and their microtubule polymerization activity.
Hidaka M; Koga T; Kiyota H; Horiguchi T; Shi QW; Hirose K; Uchida T
Biosci Biotechnol Biochem; 2012; 76(2):349-52. PubMed ID: 22313785
[TBL] [Abstract][Full Text] [Related]
20. The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance.
Ferlini C; Raspaglio G; Mozzetti S; Cicchillitti L; Filippetti F; Gallo D; Fattorusso C; Campiani G; Scambia G
Cancer Res; 2005 Mar; 65(6):2397-405. PubMed ID: 15781655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
